[go: up one dir, main page]

WO2007080174A3 - Chimeric and humanised anti-human il-13 antibodies - Google Patents

Chimeric and humanised anti-human il-13 antibodies Download PDF

Info

Publication number
WO2007080174A3
WO2007080174A3 PCT/EP2007/050219 EP2007050219W WO2007080174A3 WO 2007080174 A3 WO2007080174 A3 WO 2007080174A3 EP 2007050219 W EP2007050219 W EP 2007050219W WO 2007080174 A3 WO2007080174 A3 WO 2007080174A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
human
chimeric
diseases
hll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/050219
Other languages
French (fr)
Other versions
WO2007080174A2 (en
Inventor
Claire Ashman
Martin John Cassidy
Jane Elizabeth Clarkson
Jonathan Henry Ellis
Trevor Anthony Kenneth Wattam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35997844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007080174(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0706481-0A priority Critical patent/BRPI0706481A2/en
Priority to JP2008549873A priority patent/JP2009523154A/en
Priority to EP07703766A priority patent/EP1976881A2/en
Priority to EA200801520A priority patent/EA200801520A1/en
Priority to AU2007204372A priority patent/AU2007204372A1/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to CA002635972A priority patent/CA2635972A1/en
Publication of WO2007080174A2 publication Critical patent/WO2007080174A2/en
Publication of WO2007080174A3 publication Critical patent/WO2007080174A3/en
Priority to IL192207A priority patent/IL192207A0/en
Priority to NO20082767A priority patent/NO20082767L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention concerns immunoglobulins, particularly antibodies which specifically bind human lnterleukin 13 (hlL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hlL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.
PCT/EP2007/050219 2006-01-11 2007-01-10 Chimeric and humanised anti-human il-13 antibodies Ceased WO2007080174A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002635972A CA2635972A1 (en) 2006-01-11 2007-01-10 Chimeric and humanised anti-human il-13 antibodies
JP2008549873A JP2009523154A (en) 2006-01-11 2007-01-10 Chimeric and humanized anti-human IL-13 antibodies
EP07703766A EP1976881A2 (en) 2006-01-11 2007-01-10 Chimeric and humanised anti-human il-13 antibodies
EA200801520A EA200801520A1 (en) 2006-01-11 2007-01-10 CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13)
AU2007204372A AU2007204372A1 (en) 2006-01-11 2007-01-10 Chimeric and humanised anti-human IL-13 antibodies
BRPI0706481-0A BRPI0706481A2 (en) 2006-01-11 2007-01-10 antibody or antigen-binding fragment thereof, humanized antibody, antigen-binding fragment, transformed or transfected recombinant host cell, methods of producing an antibody, for treating a human patient afflicted with a disease, to prevent acute asthmatic attacks in a human patient , and to reduce the frequency and / or mitigate the effects of acute asthmatic attacks on a human patient, pharmaceutical composition, kit of parts, and use of an antibody or antigen-binding fragment thereof.
IL192207A IL192207A0 (en) 2006-01-11 2008-06-16 Chimeric and humanised anti-human il -13 antibodies
NO20082767A NO20082767L (en) 2006-01-11 2008-06-16 Chimeric and humanized anti-human IL-13 antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0600488.1 2006-01-11
GBGB0600488.1A GB0600488D0 (en) 2006-01-11 2006-01-11 Immunoglobulins

Publications (2)

Publication Number Publication Date
WO2007080174A2 WO2007080174A2 (en) 2007-07-19
WO2007080174A3 true WO2007080174A3 (en) 2007-12-06

Family

ID=35997844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/050219 Ceased WO2007080174A2 (en) 2006-01-11 2007-01-10 Chimeric and humanised anti-human il-13 antibodies

Country Status (18)

Country Link
EP (1) EP1976881A2 (en)
JP (1) JP2009523154A (en)
KR (1) KR20080113201A (en)
CN (1) CN101370829A (en)
AR (1) AR058955A1 (en)
AU (1) AU2007204372A1 (en)
BR (1) BRPI0706481A2 (en)
CA (1) CA2635972A1 (en)
CR (1) CR10161A (en)
EA (1) EA200801520A1 (en)
GB (1) GB0600488D0 (en)
IL (1) IL192207A0 (en)
MA (1) MA30156B1 (en)
NO (1) NO20082767L (en)
PE (1) PE20081185A1 (en)
TW (1) TW200736274A (en)
WO (1) WO2007080174A2 (en)
ZA (1) ZA200805526B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9684000B2 (en) 2010-12-16 2017-06-20 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US11453727B2 (en) 2007-10-15 2022-09-27 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
TWI422387B (en) 2006-05-25 2014-01-11 Glaxo Group Ltd Immunoglobulins
EP2358754A1 (en) * 2008-11-26 2011-08-24 Glaxo Group Limited Ligands that bind il-13
PE20160653A1 (en) * 2009-03-05 2016-07-24 Abbvie Inc IL-17 BINDING PROTEINS
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EA201190275A1 (en) * 2009-05-28 2012-11-30 Глаксо Груп Лимитед PROTEIN CONNECTING INTERLEUKIN-13 (IL-13)
PL3037104T3 (en) 2009-10-20 2020-11-16 Abbvie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
JP2013544235A (en) * 2010-10-15 2013-12-12 メドイミューン・リミテッド Treatment to improve lung function
EP2686014A1 (en) 2011-03-16 2014-01-22 Sanofi Uses of a dual v region antibody-like protein
AR098155A1 (en) 2013-10-23 2016-05-04 Genentech Inc METHODS TO DIAGNOSTIC AND TREAT EOSYNOPHYL DISORDERS
JP2017507939A (en) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド Anti-IL-13 / IL-17 bispecific antibody and use thereof
CN106536754B (en) 2014-04-11 2021-04-16 诺华股份有限公司 Methods of selectively treating asthma with IL-13 antagonists
CN107430117A (en) 2015-03-16 2017-12-01 豪夫迈·罗氏有限公司 Detection and quantitative IL 13 method and the purposes in diagnosing and treating Th2 relevant diseases
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
EP3572426A4 (en) * 2017-01-23 2020-12-23 Toyo University ANTI-EPHA2 ANTIBODIES AND IMMUNOLOGICAL DETECTION OF EPHA2 THEREFORE
CN109776677B (en) * 2017-11-15 2023-11-03 尚华科创投资管理（江苏）有限公司 Humanized anti-IL-13 antibody and preparation method and application thereof
CN107909501B (en) * 2017-12-05 2020-12-01 创新先进技术有限公司 Correlation method of smell and behavior, smell socialization method and device
PE20211304A1 (en) 2018-02-09 2021-07-20 Genentech Inc THERAPEUTIC AND DIAGNOSTIC METHODS FOR INFLAMMATORY DISEASES MEDIATED BY MASTOCYTES
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
JP2022525703A (en) * 2019-03-20 2022-05-18 ジャベリン・オンコロジー・インコーポレイテッド Anti-ADAM12 antibody and chimeric antigen receptor, and compositions and methods comprising them.
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019975A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
WO2005062967A2 (en) * 2003-12-23 2005-07-14 Tanox, Inc. Novel anti-il 13 antibodies and uses thereof
WO2006003407A2 (en) * 2004-07-01 2006-01-12 Glaxo Group Limited Chimeric and humanised monoclonal antibodies against inteleukin- 13
US20060073148A1 (en) * 2004-06-17 2006-04-06 Wyeth IL-13 binding agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019975A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
WO2005062967A2 (en) * 2003-12-23 2005-07-14 Tanox, Inc. Novel anti-il 13 antibodies and uses thereof
US20060073148A1 (en) * 2004-06-17 2006-04-06 Wyeth IL-13 binding agents
WO2006003407A2 (en) * 2004-07-01 2006-01-12 Glaxo Group Limited Chimeric and humanised monoclonal antibodies against inteleukin- 13

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453727B2 (en) 2007-10-15 2022-09-27 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
US9684000B2 (en) 2010-12-16 2017-06-20 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US9995755B2 (en) 2010-12-16 2018-06-12 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US11226341B2 (en) 2010-12-16 2022-01-18 Genentech, Inc. Method of treating asthma using an IL-13 antibody

Also Published As

Publication number Publication date
ZA200805526B (en) 2009-10-28
AU2007204372A1 (en) 2007-07-19
CA2635972A1 (en) 2007-07-19
CN101370829A (en) 2009-02-18
EA200801520A1 (en) 2009-02-27
KR20080113201A (en) 2008-12-29
GB0600488D0 (en) 2006-02-22
TW200736274A (en) 2007-10-01
IL192207A0 (en) 2008-12-29
BRPI0706481A2 (en) 2011-03-29
PE20081185A1 (en) 2008-10-07
NO20082767L (en) 2008-10-06
EP1976881A2 (en) 2008-10-08
JP2009523154A (en) 2009-06-18
MA30156B1 (en) 2009-01-02
WO2007080174A2 (en) 2007-07-19
AR058955A1 (en) 2008-03-05
CR10161A (en) 2008-11-26

Similar Documents

Publication Publication Date Title
WO2007080174A3 (en) Chimeric and humanised anti-human il-13 antibodies
WO2006003407A3 (en) Chimeric and humanised monoclonal antibodies against inteleukin- 13
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
WO2007045477A8 (en) Human antibodies against il-13 and therapeutic uses
WO2008123999A3 (en) Anti-ige antibodies
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
EP2270049A3 (en) Recombinant anti-interleukin-9-antibody
WO2011160119A3 (en) Anti-gd2 antibodies
WO2010021874A3 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
WO2007036745A3 (en) Interleukin-13 antibody composition
WO2005061544A3 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
WO2008055206A3 (en) Humanized anti-factor d antibodies
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
WO2009001840A1 (en) Anti-prominin-1 antibody having adcc activity or cdc activity
WO2005012493A3 (en) Anti-cd19 antibodies
WO2009048537A3 (en) Humanized antibody
WO2008115732A3 (en) Anti-sclerostin antibodies
WO2009151717A3 (en) Bcr-complex-specific antibodies and methods of using same
WO2006104677A3 (en) Antibodies that bind ov064 and methods of use therefor
WO2007098420A3 (en) Peptides that block the binding of igg to fcrn
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007204372

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 569437

Country of ref document: NZ

Ref document number: 08066119

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2681/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008071151

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2008549873

Country of ref document: JP

Ref document number: 2007703766

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007204372

Country of ref document: AU

Date of ref document: 20070110

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/008946

Country of ref document: MX

Ref document number: 2635972

Country of ref document: CA

Ref document number: 12008501634

Country of ref document: PH

Ref document number: 200801520

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2007204372

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200780002297.3

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: CR2008-010161

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: DZP2008000499

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1020087019555

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: a200808084

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0706481

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080710